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Background: Antibiotics resistance threats Tuberculosis control, being crucial to work on unbi- 
ased MDR-TB images. The decision of testing is clinical, non-random, raising extrapolation prob-
lems. Aim: To evince and describe non-random testing practices; develop and apply a coherent 
and intuitive method for estimating global corrected resistance prevalences (2000-2009). Meth-
ods: A quantitative approach upon National Tuberculosis Database was undertaken, to assess 
testing potential predicting factors. Different factors structures in tested and non-tested cases 
were characterized (regarding socio-demographic and clinical variables), through binary logistic 
regressions. Estimated multirresistance prevalences were corrected using the essayed model. 
Results: Only 32% of cases had been tested, where MDR-TB prevalence was 2.38%. All factors in-
fluenced the practice of testing (p < 0.05). Corrected resistance estimates in non-tested ranged 
1.96% - 2.71%, and the global weighted average found ranged 2.07% - 2.51%, depending on the 
chosen strata structure. Conclusions: MDR-TB prevalence representation must consider patients’ 
characteristics influencing testing. The correction method improved prevalences interpretation 
substantially; corrected and conventional values were close, because tested and non-tested had 
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Epidemiological information is showing consistent improvements in Tuberculosis (TB) control worldwide. In-
cidence rate is falling since 2002 and mortality is decreasing since the 90s; however TB remains a major Public 
Health burden in most developing countries, in part due to the HIV epidemic [1] [2]. In Portugal, HIV 
co-infection (about 15% of new TB cases [3]), social and behavioral factors and some inefficiencies of health 
services may explain difficulties in achieving a better control [4]. Progresses must be promoted, particularly in 
higher risk districts, probably under unfavorable socioeconomic, cultural and organizational influences [4]. Cur-
rent economic crisis may also counteract control efforts [1]. 
A sufficiently high both new cases detection (>70%) and treatment success (>85%) are established as mile-
stones for achieving an acceptable control in a population [2]. Among factors influencing treatment success, the 
susceptibility of patients’ bacilli to appropriate antibiotics is obviously crucial [5]. Since 1994, World Health 
Organization (WHO) alerted for the insufficient information about drug resistant Tuberculosis (DR-TB), espe-
cially in developing countries, and created the Global Project on Drug Resistance Surveillance [6] [7]. It is a 
matter of increasing concern, with an unfavorable trend and the stagnancy of antibiotic resources.  
Multidrug Resistant Tuberculosis (MDR-TB) occurs when strains of Mycobacterium tuberculosis are resistant 
to at least both Isoniazid (H) and Riphampicin (R) [8]. DR-TB emerged after the introduction of effective TB 
treatment as a generalized practice, and MDR-TB has been reported in every country where this phenomenon 
has been surveyed [9]-[11]. First-line antibiotics, especially H and R, are more potent and usually better toler-
ated than second-line ones. Consequently, resistance to first-line drugs leads to longer, more expensive treat-
ments (at least 20 months, vs 6 months) [1] and often predicts unsuccessful treatment courses (cure rates: 60% to 
75% vs around 90%), in non HIV-infected patients [12] [13]. In addition, MDR-TB and unsuccessful treatment 
show a dual reinforcement, because they are both predictor and consequence of each other [13]. 
Some risk factors are known for a case to be drug resistant, as previous treatment, male sex and HIV co-in- 
fection [13]. In countries where HIV infected and TB populations overlap more deeply, a faster increase of 
MDR-TB has been observed [14] [15].  
In Portugal, TB endemics has a medium-low level at a world scale (in 2010, notified incidence rate was 23.2 
× 10−5), representing the least favorable situation in Western Europe, though reducing slowly but firmly [3] [4], 
[16]. Since 2000, Portugal improved its Tuberculosis Surveillance System (SVIG-TB), following WHO recom-
mendations, and it is categorized as Class A, the highest classification for the quality of such data [15]. The 
Portuguese Directorate-General of Health publishes annual reports about the TB epidemiological situation [3] 
[17] [18]. In 2010, officially reported resistance to both H and R (H∩R) was of 1% in new cases and 5.2% in re-
treatments. These proportions are low, at a worldwide level [15]. However, a study published in 2000, designed 
to understand resistant TB in Portugal, revealed relevant proportions of acquired resistance [19]. 
Expressing and interpreting results for Drug Susceptibility Tests (DST) can be difficult. The specificity and 
validity variability of methods used for antibiotics testing may influence results [20]; and MDR-TB studies un-
dergo small numbers problems frequently; lastly, it is not possible to test all cases, or a random sample of them, 
because patients don’t all have the required biological specimen available; and DST may be rationally requested, 
depending on particular patients’ characteristics and on clinicians’ experiences [21]. Beyond the fact that bacilli 
in non-tested may also have or develop resistances to some antibiotics, the non-random physicians’ decisions 
may create a selection bias that will distort the final proportion of resistant cases (Figure 1).  
Should MDR-TB occurrences found in tested cases be considered as representative of the total number of 
MDR-TB cases in all notified cases? Or MDR-TB cases found depend on who is tested, representing a non- 
random sample of the total MDR-TB cases? 
According to the conventional calculation process, estimates of resistance prevalences assume that tested 
cases are representative of the whole notified TB cases [22]. Authors believe that such an assumption is not re-
liable enough, however, as referred to. 
A method liable to deal with the described bias is necessary. Methodologically, this can be framed in a non- 
probability sampling context, because the selection of elements was based on assumptions regarding the popula-
tion of interest, as opposed to a random selection. These conditions give rise to an exclusion or selection bias, 
imposing limits on how much and how good information a sample can provide about the population, making it 
difficult to extrapolate to it. This sampling method can be called as “Intentional”, where the cases are selected 
based on who they (doctors) think would be appropriate for the study (testing), drawn on both theory (i.e., scien-
tific literature) and experience, thus not giving to all individuals in the population (TB cases) equal chances  





Figure 1. From having Tuberculosis to being test- 
ed: some non-tested patients may be resistant and 
some factors may be predictive for testing.                 
 
of being selected. But a purely random selection for testing would involve ethical problems in the field setting, 
of course [23].  
In this intentional sampling, certain members (i.e. HIV-positive) can be either underrepresented or overrepre-
sented relatively to others in the population. The proposed method to correct the global MDR-TB prevalence is 
based on the comparison of the characteristics of tested cases, with those of non-tested, and ends up by synthe-
sizing an all-cases global value, weighted for strata dimensions.  
Thus, who were the patients in fact tested in practice? What was the importance of the tested patients’ struc-
ture regarding their characteristics, as compared with non-tested? And how can this knowledge help to get a 
proportionate, contextualized view of the overall resistance profile? 
On such basis, this essay aimed to: 1) describe and analyze non-random testing practices; 2) develop and as-
sess a coherent and intuitive method for calculating TB global resistance prevalences, which could take into ac-
count testing reality; and 3) estimate MDR-TB prevalences for 2000-2009 in Portugal, using each approach. A 
contribution for sounder decisions in control was envisaged. 
2. Methods 
This study had a strong methodological component, focusing non-probabilistic sampling, and was based on 
SVIG-TB database, regarding the period 2000-2009.  
Detecting a MDR-TB case can be the end of a complex non-random process, expressed as a conditional 
probability chain of major steps. A model representation of this chain was built up from SVIG-TB, where the 
number of patients known or estimated in each step, in 2000-2009, was identified. Each percentage between 
steps was interpreted as the probability of moving between successive stages. 
Notified cases with all kinds of clinical expression were included, as a specimen for culture can be obtained 
from any clinical presentation, virtually [24]. After a descriptive exploration to testing and treatment practices 
and the corresponding results, an internal case-control analysis was undertaken. Tested patients were the “cases” 
and several alternatives for defining the “control group” were faced; all other (non-tested) patients were included 
in this group at last, because they were acceptable as sufficiently comparable with “study cases”. Such limit-op- 
tion ended up configuring a cross-sectional approach. 
Available variables selected as possible predictors of being tested were: sex, age, HIV serology (positive or 
negative), previous treatment (presence or absence), being drug abuser (yes or no), being alcoholic: yes or no 
[25], and country of birth (natives or foreigners). 
As to the response variable, only the initial DST undertaken was considered, because: 1) SVIG-TB records 
the first and the last DST for each patient merely, meaning that the last test might correspond to different mo-
ments in follow-up for different cases; 2) it was expected to assess the existence of predicting factors for the first 
testing, which was the one relevant for initial treatment definition, in the current scope.  




Although only patients tested for H∩R were focused, an initial descriptive study was done considering all an-
tibiotics tested.  
A binary logistic regression permitted to explore relationships between TB cases being tested to H∩R and 
their exposure to a selection of relevant factors predicting testing; the two structures of exposure to these factors 
in study groups (cases and controls) were compared through odds ratios (a proxy to the relative probabilities of 
being tested, according to exposure statuses). Crude and adjusted ratios were used to identify such factors, as 
well as their degree of association with the response variable. PASW Statistics Software (version 18) was used 
and 95% confidence intervals were calculated, when suitable. 
An overall prevalence of MDR was estimated, based on two different approaches: 1) the classical one, as-
suming the prevalence in tested cases as a competent proxy to global prevalence, considering the sample tested 
as representative of all cases, similar to the result of a random selection of cases to be tested; 2) a corrected 
prevalence estimation, considering the differences in distributions of characteristics found to predict testing, 
between tested and non-tested cases, as detailed next. 
The Correcting Method 
Assuming that in practice the tested sample wasn’t random, this method intended to yield a corrected estimate of 
the prevalence of MDR-TB resistant occurrences in all cases, allowing for the differences between the distribu-
tions of tested and non-tested, regarding characteristics found to predict testing. 
Logistic regression models were applied to identify which variables were relevant, for predicting the prob-
ability of being tested. If there were no evidence of different distributions between tested and non-tested cases, 
the classical approach could be taken (as equal estimates using either method would result).  
Underlying assumptions were carefully defined, and attention was paid to the potential biasing effect of ex-
cluding cases, because of missing values for any variable.  
An important aspect was the assumption that resistance prevalences were equal in equivalent strata in tested 
and non-tested groups (stratification based on identified predicting factors).  
The definition of the factor stratification structure in either tested or non-tested was undertaken, in accordance 
with several combinations of classes of the factors predicting testing, allowing a specific prevalence estimate for 
each stratum in non-tested.  
For each scenario (each set of characteristics considered for the definition of strata structure), the following 
method was applied:  
1) Considering the identified variables ( ), , ,X Y I , each group (tested or non-tested) was therefore broken 
down into a system of cells, or strata ( ), , ,a b iX Y I ;  
2) For each cell in tested, known resistance prevalence in stratum ( ), , ,a b iX Y I , ( ), , ,RT a b iP X Y I , was 
identified: 
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where ( ), ,,RT a b in X Y I  is the number of resistant tested cases in stratum ( ), , ,a b iX Y I ; ( ), , ,T a b in X Y I  
is the number of tested cases in ( ), , ,a b iX Y I ; 
3) In non-tested stratum ( ), , ,a b iX Y I , the number of estimated resistances cases to H∩R was calculated 
( ), ,,RNT a b in X Y I , by applying the specific proportion of resistances found in this stratum in tested cases: 
( ) ( ) ( ), , ,, , , , , ,RNT a b i RT a b i NT a b in X Y I P X Y I n X Y I= ×   ; 
where ( ), ,,NT a b in X Y I  is the number of non-tested cases in stratum ( ), , ,a b iX Y I ; 
4) The total number of resistant cases (nR) was given by the sum of all resistant cases identified among tested, 
plus the number of resistant cases estimated to exist in non-tested, across all strata: 
( ) ( ), , , , , , ;R RT a b i RNT a b ia b i a b in n X Y I n X Y I= +∑ ∑ ∑ ∑ ∑ ∑     
5) The global proportion of corrected resistances (%PCR) was given by the total resistant cases (nR), in either 








Figure 2 illustrates the process for a given stratum (previous steps 1 to 3), considering a combination of  





Figure 2. Estimating resistances in non-tested cases, for a given cell (Sex (X) = F, Previous 
Treatment (Y) = 0, Age (Z) = 35 - 44).                                                     
 
classes of a selected set of factors that might predict the decision of testing. 
Therefore, estimated resistances numbers in non-tested cases cells were added up across all cells, allowing a 
corrected total estimate for this group. Cases with missing values in age, sex or number of treatments were not 
considered. As shown, the described approach is conceptually akin to standardization. Some methodological 
comments are included in next chapter, acting as contexts for results. 
3. Results 
3.1. From Having Tuberculosis to Being Identified as a MDR-TB Case 
Figure 3 is represents the conditional probability chain of a patient to become identified as a MDR-TB case; the 
number of patients known (in bold) or estimated, in 2000-2009, is shown. Depending on how the global propor-
tion of MDR-TB cases was calculated (different scenarios and denominators), a diversity of probabilities of be-
ing resistant among notified cases could be estimated, from exactly the same count of resistants (390). This 
quantifies the diagram in Figure 1. 
The first node’s dimension (58,600) was estimated based on the Portuguese notification rate (87%) made by 
WHO [26] and considering all Portuguese cases notified in 2000-2009 (50,982). Although 68% of positive cul-
tures were tested for MDR-TB, out of the total notified cases only 32.2% were actually tested for MDR-TB 
(16,396 cases). Even more, the same proportion of cases (32.2%) was tested for H, R, and H∩R. 
3.2. Drug Susceptibility Testing (DST) Frequencies 
Testing frequencies for H, R, Z, E and S had much greater magnitudes as compared to testing for second-line 
antibiotics (Figure 4). 
3.3. Estimating Multi Drug Resistances 
Classical Approach (1) 
The classical approach takes prevalence in tested cases as a convenient proxy of the prevalence in all cases. 
Considering that 390 MDR-TB cases were identified among the 16396 tested cases, a global estimated percent-
age of 2.38% of MDR-TB was obtained (equal prevalence in non-tested cases assumed and not considering the 
effects of possible factors that may promote or prevent testing). 
The Correcting Method (2) 
The principle is that, if the group of tested and the group of non-tested differ in characteristics that may pre-
dict testing practices and, possibly, resistance to antibiotics, then the previously calculated proportion must be 
corrected for such differences. As a result of logistic regressions, Figure 5 and Figure 6 show that the exposure 
to some factors was, in fact, likely to predict different probabilities of being tested, in concordance with Figure 1.  





Figure 3. Tentative conditional probability chain, from having Tuberculosis to being identified 
as a MDR-TB case (Portugal, 2000-2009; counts [bold], estimates and %). Model based on 
SVIG-TB.                                                                       
 
 
Figure 4. Frequencies (%) of testing to each antibiotic, among total TB cases (2nd line antibi-
otics zoomed). Legend: Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E), 
Streptomycin (S), Thiacetazone (Tiac), Kanamycin (Kana), Amikacin (Amic), Capreomycin 
(Capr), Ethionamide (Etio), Ciprofloxacin (Cipr), Ofloxacin (Oflo), Cycloserine (Cicl), 
Para-Amino Salicylic acid (PAS), Rifabutin (Rifb) and Clofazimine (Clof).                    
 
Being male looked a predictor for increased initial DST undertaking (OR = 1.51; CI95%: 1.43 - 1.60), simi-
larly to alcoholic patients (OR = 1.61; CI95%: 1.50 - 1.74). Having at least one previous treatment was also a 
predicting factor for testing (OR = 1.40; CI95%: 1.29 - 1.53). Interestingly, foreigners were almost as likely to 
be tested as native patients (OR = 1.11; CI95%: 1.03 - 1.20); and drug addicts (OR = 0.91; CI95%: 0.83 - 0.99) 
and HIV positive (OR = 0.66; CI95%: 0.61 - 0.71) patients seemed less likely to be tested than non-drug addicts 
and HIV negative patients, respectively. Age was an important predictor for testing, with a heterogeneous im-
pact (Figure 6). 





Figure 5. Odds Ratios for some factors predicting MDR-TB testing, crude (Δ) and adjusted to all vari-
ables analyzed ( ), and 95% CI, depending on characteristics of TB patients. Portugal, 2000-2009.                
 
  
Figure 6. Odds Ratios for age groups predicting MDR-TB testing of TB patients, Portugal, 2000-2009, 
crude (Δ) and adjusted ( ), and 95% CI; reference class: <25 years.                               
 
All the studied predicting dimensions did seem to influence the probability for cases to be tested to H∩R 
anyhow, and in various degrees. Given the different exposure structures in tested and non-tested, the correcting 
estimation method was essayed, as follows. 
Table 1 summarizes results of this approach in the Portuguese context (2000-2009), according to different 
predictor combinations. The set of factors selected for elaborating Figure 2 is underlined. Factors with major 
proportions of cases excluded because of missing values were less appropriate for correction, as these might 
produce some kind of uncontrolled bias—missing data may be associated with one or several predictors. 
Depending on the factors considered, resistances’ estimates in non-tested varied, and were different from the 
non-corrected ones, in the total number of notified cases. E.g., if the proportion of resistances was corrected for 
age and sex, 50,755 notified cases were included; however, if the correction was also made for HIV, only 30,000 
cases could be included. This happened because the HIV variable had 40.9% of cases with missing values; these 
couldn’t enter the estimation procedure. 
The summary assessment of both the construct validity and functionality of the described correcting model 
indicated it’s appropriateness for the purpose and, furthermore, suitability for other analogous situations. 
As Table 1 shows, correcting estimates yielded slightly lower prevalence values, as expected, meaning that 
tested patients had, in fact, a higher risk of being MDR-TB cases, in the Portuguese setting. From all correction 
criteria presented, that one combining sex, age, retreatment and country of origin was considered more accurate 
(bold) than the others, as it included 4 variables with low missing values numbers (0.68%). 




Table 1. Estimations of resistant cases and prevalences in non-tested and in all cases, as a function of different sets of factors 


















cases in all 
casesb 
% resistants 
in all casesb 
% missing 
values 
Nonec 50,982 16,396 390 2.38 34,586 823 1213 2.38 - 
Sex + Age 50,755 16,336 390 2.39 34,419 791 1181 2.33 0.44 
Sex + Age + Ret 50,755 16,336 390 2.39 34,419 711 1101 2.17 0.44 
Sex + Age + Country 50,636 16,307 389 2.39 34,329 773 1162 2.29 0.68 
Sex + Age + Alc 45,667 14,878 339 2.28 30,789 668 1007 2.21 10.42 
Sex + Age + Drug 45,468 14,764 335 2.27 30,704 673 1008 2,22 10.82 
Sex + Age + HIV 30,000 12,906 343 2.66 17,094 463 806 2,69 41.16 
Sex + Age + Ret + 
Country 50,636 16,307 389 2.39 34,329 696 1085 2.14 0.68 
Sex + Age + Ret + 
Alc 45,607 14,848 341 2.30 30,759 615 957 2.10 10.54 
Sex + Age + Ret + 
Drug 45,468 14,764 416 2.82 30,704 726 14,724 2.51 10.82 
Sex + Age + Ret + 
Country + Alc 45,590 14,852 342 2.30 30,738 602 944 2.07 10.58 
aTested + non-tested. bEstimated by correcting method. cClassical Approach; Legend: Ret—Retreatment, Alc—alcholism, Drug—Drug abuse. 
4. Discussion 
To know the proportion of MDR-TB cases involves a complex decision chain. Although 68% of positive cul-
tures were tested for DST among notified cases, only 32% of these were actually tested for H∩R, in 2000-2009. 
This probably happens because: 1) notified cases need to be able to provide a biologic product for testing (usu-
ally sputum; but it can be other specimen) and it must be submitted to at least one culture and its result must be 
positive, so that a DST is possible; 2) depending on the physician’s options and on healthcare facilities, smear 
positive cases may not be tested for any antibiotic. Admitting that medical care options play the principal role in 
the decision of who is tested, testing preferences found were rather coherent with predicting factors for unsuc-
cess, as known from the literature.  
This essay is focused on MDR-TB cases, because of their importance in TB control; but results of tests to 
both antibiotics, as shown in Figure 4, need to be interpreted in the appropriate practical context. Frequencies 
presented in Figure 4 are quite expected, but some concern about the comparability of resistances proportions 
between first-line and second-line antibiotics must be raised; tested cases are the denominators of resistance 
proportions, and second-line antibiotics are far less tested; therefore, proportions are much less accurate here. 
Moreover, DST technology reliability is not considered in estimations, but it depends on the antibiotic to be 
tested [20] and may also vary in space and time. Meanwhile, discussing the interest of these “in vitro” tests for 
the field control of TB is out of the scope of this paper, but “in vivo” antibiotics synergy in each combination 
pack and with the patient’s self-defense mechanisms should not be devalued.  
The conditional probability chain (Figure 3) was elaborated from SVIG-TB data. This doesn’t allow a dis-
tinction between cases that weren’t tested because there wasn’t a specimen available, from cases that weren’t 
tested for other reasons. Therefore, all cases were included in the regression, although only patients with both an 
available biologic product for analysis and a positive culture should have been included; these were the only 
really liable to be tested. Moreover, it is not possible to assess whether the decision for testing was made exclu-
sively by the physician, or whether the health institution or laboratory staff was also involved.  
In the presented approach, as mentioned, all non-tested patients were included as “controls” for tested, be-
cause: 1) the resistance phenomenon and a specimen collection for testing could virtually occur in any of them, 
with a variable degree of invasiveness; and 2) a narrower selection of “controls” would raise additional hamper-
ing small numbers difficulties. In all alternatives, the so complex web of relationships found and the mentioned 
uncertainty could facilitate possible confounding effects of the very testing predictors on future resistance pro-




portions, as such factors may also explain either the real availability of a specimen for culture, or a positive cul-
ture [27]. Therefore, in the context of the present essay, tested and non-tested may be taken as comparable 
enough for the purpose and caution expressed about this issue outlines the risks of this assumption appropriately. 
Particularly, if “predictors for testing” have a marked low prevalence in the (unknown) patients really not pro-
viding a specimen for culture, the weight of these patients as “controls” will tend to increase the final odds ratio 
estimates. Anyway, the resistance prevalence ends up being generalized to all notified cases, for control pur-
poses, which is a rather blind decision. 
Measurements validity regarding studied variables closely depended on the original data on associated prac-
tices. E.g., zooming on HIV infection status, a similar practice of selective diagnostic testing may have occurred, 
representing another source of bias: HIV-positive patients seemed less likely of being tested for H∩R than 
HIV-negatives, due to the fact that clinicians may tend to decide directly and blindly for prescribing second-line 
antibiotics to HIV-positive patients. 
As previously known [28], selected factors predict testing practices and these also change throughout time. 
Studies should focus on short periods of time (e.g. biannual) ideally, as a good monitoring, and face possible 
small numbers problems. 
Estimating resistances in non-tested cases, allowing for predictors of testing, means that tested and non-tested 
only differ in the characteristics studied, which may not be true. Ideally, all characteristics previously estab-
lished in literature as predictors for MDR-TB should be considered. In this study, previous contact with a 
MDR-TB case, a characteristic likely to suggest MDR-TB testing, was not included due to unavailability of such 
data. However, this characteristic in a country such Portugal would probably not affect the results, because al-
most all patients known to be in contact with MDR-TB are very likely to be tested. A qualitative study regarding 
determinants for testing could be useful for further studies. 
Also the presence of missing values is an important limitation and careful decisions must be taken. In the case 
of low percentages of missing values (<10% as an indicative and subjective value), more risk factors could be 
considered for adjustment. In other situations (≥10%), it could lead to a loss of considerable number of cases 
and could introduce further bias. Therefore, theoretically, this approach should embrace the greatest number of 
identified variables and reject those with high numbers of missing values, simultaneously. Complementary to 
the missing data problem, the quality of data is another issue that should be considered in the variables’ choice.  
Odds ratios for HIV must be cautiously valued, as a too high a proportion of cases was excluded (missing 
values = 40%). Variables such as drug addiction and alcoholism have less missing values cases (near 10%), but 
their measurement is very subjective and may be heterogeneously interpreted by medical staff. Corrections for 
age, sex, retreatment and country of origin (all with few missing values cases and higher odds ratio values) 
seemed, in this specific situation, an appropriate choice.  
In the proposed method, the similarity of resistance proportions in corresponding strata, in tested and 
non-tested, was assumed. Lower global resistance proportions would be obtained if smaller resistance preva-
lence were assumed, with the same correction criteria regarding predictors for testing. Our more conservative 
option in this essay is prudent, in the absence of further local appropriate information. 
All methodological limitations don’t wipe the evidence that selection criteria for testing, in Portugal, artifi-
cially increase the global resistance prevalence value slightly, when a non-corrected calculation is used. But in 
other contexts where laboratory facilities are less available, these criteria may act more intensely, generating 
major differences between tested and non-tested structures and resulting in a larger distortion. 
The simplicity, the intuitiveness and the internal coherence of the essayed method make it, in fact, suitable as 
a solution for similar estimation problems, in analogous situations. 
5. Conclusions 
From the occurrence of a new case in the population, until finding a resistance in a notified case, a complex 
chain of conditional events happened.  
They differed in several degrees and different ways regarding studied predicting factors for testing: sex, age, 
drug abuse, alcohol abuse, country of origin, number of previous treatments, HIV co-infection.  
Generalizing DST results from tested patients to non-tested straightforwardly can lead to a relevant distortion 
of the global resistance prevalence estimate, when some patients’ characteristics either increase or decrease DST 
undertaking practice. This can be a major shortcoming, when using the conventional estimation approach. 
In the Portuguese setting, crude (2.38%) and corrected (2.14%) (for age, sex, country and retreatment) 




MDR-TB prevalences estimated for 2000-2009 were rather similar; however, in other settings, where patients’ 
characteristics are even more determinant in the decision of testing, thus making tested and non-tested differ 
more drastically, those estimates can be much distinct, resulting in major implications for monitoring and deci-
sion making. 
The method now developed and essayed for resistance prevalence correction is a coherent, simple and intui-
tive approach, easy to replicate when the required input information is available and appropriate assumptions are 
made. It is able to facilitate the interpretation of such prevalence and to improve consequent decisions. Method’s 
features make it suitable, by analogy, for improving proportions estimation in other similar situations.  
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